Results 311 to 320 of about 158,388 (335)

The face of remission induction

British Journal of Haematology, 2019
SummaryAcute myeloid leukaemia (AML) is a heterogeneous disease in which prognosis is determined by cytogenetic and molecular aberrations as well as patient‐related factors, including age, prior haematologic disorders, and comorbidities. Despite the diverse disease biology, the standard of care for remission induction therapy has changed very little ...
Shilpa Paul, Caitlin R. Rausch, Elias J. Jabbour   +2 more
openaire   +3 more sources

Natalizumab for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2006
The pathogenesis of Crohn's disease involves migration of leukocytes into gut tissue and subsequent inflammation. Natalizumab (Tysabri(R), Elan Pharmaceuticals and Biogen Idec) a recombinant humanized IgG4 monoclonal antibody that blocks adhesion and subsequent migration of leukocytes into the gut by binding the alpha4 integrin is a member of a new ...
John Wd McDonald, John K MacDonald
openaire   +4 more sources

Budesonide for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2015
Corticosteroids are commonly used for the induction of remission in Crohn's disease. However, traditional corticosteroids can cause significant adverse events. Budesonide is an alternative glucocorticoid with limited systemic bioavailability.The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission ...
Anthony Otley, Gilaad G. Kaplan, A. Hillary Steinhart, Cynthia H. Seow, Anne M. Griffiths, Ali Rezaie, M Ellen Kuenzig, Eric I Benchimol, Eric I Benchimol   +8 more
openaire   +3 more sources

Methotrexate for induction of remission in ulcerative colitis

2007
Ulcerative colitis is a chronic inflammatory bowel disease. Corticosteroids and 5-aminosalicylates are the most commonly used therapies. However, many patients require immunosuppressive therapy when their disease becomes steroid-refractory or dependent.
N, Chande, J K, MacDonald, J W D, McDonald   +2 more
openaire   +2 more sources

INDUCTION OF REMISSION IN HEPATOCELLULAR CARCINOMA WITH DOXORUBICIN

The Lancet, 1978
Doxorubicin (60 mg/m2 at 3-weekly intervals to a maximum total of 550 mg/m2) induced clinical remission in 14 (32%) of 44 patients with hepatocellular carcinoma. In 3 of those who responded, hepatic arteriography showed clearing of the previously extensive tumour circulation, and in a 4th there was disappearance of the tumour on serial ultrasound ...
Roger Williams, Roger Williams, Roger Williams, Sheila Sherlock, Sheila Sherlock, Sheila Sherlock, Philip J. Johnson, Philip J. Johnson, Philip J. Johnson, Howard Thomas, Howard Thomas, Howard Thomas, I. M. Murray-Lyon, I. M. Murray-Lyon, I. M. Murray-Lyon   +14 more
openaire   +3 more sources

Probiotics for induction of remission in ulcerative colitis

2006
Ulcerative Colitis (UC) is an inflammatory condition affecting the colon with an incidence of approximately 10-20 per 100,000 per year. No existing intervention is effective in all patients with a proportion requiring colectomy. There are significant proportion of patients who experience adverse effects with current therapies.
Keith Gardiner, Damian McKay, Steven J Kirk, Peter T Mallon   +3 more
openaire   +3 more sources

Cyclosporine for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2005
Cyclosporine was first found to be an effective and well-tolerated immunosuppressive agent in organ transplant recipients, and subsequently in several autoimmune diseases. It was reported in open studies that cyclosporine is effective for induction of remission in Crohn's disease.
John K MacDonald, Derek P. Jewell, Brian G. Feagan, Eduard F. Stange, John W.D. McDonald, Jørn Brynskov   +5 more
openaire   +3 more sources

Budesonide for induction of remission in Crohn's disease

1996
Corticosteroids continue to play a central role in induction of remission in active Crohn's disease. However, their use comes at a price of significant adverse effects when used repeatedly or for extended periods. Newer corticosteroid agents with limited systemic bioavailability offer a tantalizing option, if they can be shown to be efficacious and ...
A, Otley, A H, Steinhart
openaire   +2 more sources

Induction of remission in rheumatoid arthritis: criteria and opportunities

Rheumatology International, 2008
The concept of remission in rheumatology is complicated by the lack of a single gold standard measurement, spontaneous remissions and the usage of several sets of remission criteria. Feasibility is reduced by traditional clinical practice, which does not include remission criteria monitoring.
VALESINI, Guido, DI FRANCO, Manuela, SPINELLI, FRANCESCA ROMANA, SCRIVO, Rossana   +3 more
openaire   +4 more sources

Fish oil for induction of remission in ulcerative colitis

Cochrane Database of Systematic Reviews, 2006
Fish oil supplements, which are rich in n-3 fatty acids, may reduce inflammation, decrease the need for anti-inflammatory drugs, and promote normal weight gain in people with ulcerative colitis.This review evaluates the efficacy of fish oil for induction of remission in ulcerative colitis using all available randomised controlled trials.The Cochrane ...
Daniel W Hommes, Maartje de Ley, Pieter C. F. Stokkers, Rien de Vos   +3 more
openaire   +3 more sources